Blog Posts

DOSE OF REALITY: BIG PHARMA’S EGREGIOUS GLP-1, GENE, AND CELL THERAPY PRICES PROJECTED TO INCREASE HEALTH CARE COSTS FOR EMPLOYERS

Aug 26, 2024

Analysis Finds GLP-1 Blockbusters and “Multimillion-Dollar Gene Therapies” Read More

BIG PHARMA EARNINGS WATCH: GSK, PFIZER, MERCK, BRISTOL MYERS SQUIBB

Aug 7, 2024

Big Pharma Continues Raking in Expectation-Beating Profits and Revenue Fueled Read More

BIG PHARMA EARNINGS: SANOFI, ASTRAZENECA, ROCHE AND ABBVIE

Jul 26, 2024

More Brand Name Drug Makers Beat Wall Street Earnings After Hiking Prices This Read More

BIG PHARMA EARNINGS: JOHNSON & JOHNSON AND NOVARTIS

Jul 23, 2024

Big Pharma Giants Top Wall Street Expectations After Hiking Prices on Read More

SECOND OPINION: LATEST PHRMA AD CAMPAIGN DEFENDS PATENT ABUSE “STATUS QUO”

Jun 26, 2024

Big Pharma Advertising Blitz Seeks to Protect Anti-Competitive Tactics That Read More

DOSE OF REALITY: FORBES: HOW BIG PHARMA EXPLOITS LOOPHOLES IN THE PATENT SYSTEM

Jun 25, 2024

Avik Roy Highlights How Increased USPTO-FDA Collaboration and Greater Scrutiny Read More

DOSE OF REALITY: FORBES: HOW BIG PHARMA STIFLES COMPETITION WITH PRODUCT HOPPING

May 23, 2024

Research Column Explores Case Study in Common Patent Abuse Tactic That Read More

DOSE OF REALITY: BIG PHARMA’S PATENT ABUSE BLOCKS COMPETITION IN THE PRESCRIPTION DRUG MARKET, KEEPS DRUG PRICES HIGH

May 21, 2024

Senate Hearing Offers Opportunity to Highlight Market-Based Solutions to Hold Read More

DOSE OF REALITY: STUDY FINDS NEARLY THREE-QUARTERS OF BIG PHARMA’S PATENTS ON TOP-SELLING DRUGS FILED AFTER FDA APPROVAL

May 16, 2024

Analysis Showcases Egregious Scale of Big Pharma’s Patent Thickets on Read More